
Marker Therapeutics, Inc.
NASDAQ:MRKR
1.25 (USD) • At close April 25, 2025
Overzicht | Financiële gegevens
Bedrijfsnaam | Marker Therapeutics, Inc. |
Symbool | MRKR |
Munteenheid | USD |
Prijs | 1.25 |
Beurswaarde | 13,386,250 |
Dividendpercentage | 0% |
52-weken bereik | 0.95 - 5.99 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Dr. Juan F. Vera M.D. |
Website | https://www.markertherapeutics.com |
An error occurred while fetching data.
Over Marker Therapeutics, Inc.
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications in the United States. Its MultiTAA-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)